Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-CD79B, ACD79B-VCMMAE Vector   (CAT#: GTVCR-WQ257MR)

This product GTVCR-WQ257MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting CD79B. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_000626.4
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-CD79B, ACD79B-VCMMAE Vector (GTVCR-WQ257MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2365MR IVTScrip™ pSP6-VEE-mRNA-Anti-PCSK9, aPCSK927 Vector Vector aPCSK927
GTVCR-WQ835MR IVTScrip™ pT7-VEE-mRNA-Anti-GP, c2G4-N Vector Vector c2G4-N
GTVCR-WQ2314MR IVTScrip™ pSP6-VEE-mRNA-Anti-S, REGN-10987 Vector Vector REGN-10987
GTVCR-WQ1976MR IVTScrip™ pT7-VEE-mRNA-Anti-PDCD1, MK-3475 Vector Vector MK-3475
GTVCR-WQ1406MR IVTScrip™ pSP6-VEE-mRNA-Anti-TACSTD2, aTROP2S7 Vector Vector aTROP2S7
GTVCR-WQ1541MR IVTScrip™ pSP6-VEE-mRNA-Anti-FOLR1, IMGN853 Vector Vector IMGN853
GTVCR-WQ573MR IVTScrip™ pSP6-VEE-mRNA-Anti-Canlupfam CD52, AT-005 Vector Vector AT-005
GTVCR-WQ1941MR IVTScrip™ pSP6-VEE-mRNA-Anti-ERBB2, MGAH-22 Vector Vector MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW